Other
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.
Executive Summary
- The most recent news (2026-05-20) reports that PharmAla Biotech entered into a term sheet to grant Jupiter Neurosciences (NASDAQ: JUNS) exclusive, perpetual U.S. licensing rights to ALA‑002, its lead next‑generation MDMA candidate.
- The proposed deal is valued at over US$100 million in total, comprising: upfront consideration of $3.33 million ($1.5M cash, $1.83M in JUNS shares, with a 10‑day lock‑up on the stock), future development milestone payments, and single‑digit royalties on net U.S. sales.
- Jupiter must deposit $600,000 into escrow upon signing; if a definitive agreement isn’t executed within 90 days, PharmAla keeps that amount as a reverse termination fee.
- PharmAla retains all rights to ALA‑002 outside the U.S., including its existing commercial operations in Australia through the Cortexa JV.
- The parallel announcement from Jupiter confirms the same terms and adds that the deal was signed against the backdrop of the April 18, 2026, U.S. Executive Order designed to accelerate access to psychedelic medicines.
Material Impact
- The announcement materially validates years of R&D investment in ALA‑002, an FDA‑recognized Novel Chemical Entity engineered for better cardiovascular safety and lower abuse liability.
- Upfront cash and stock inflow improve PharmAla’s balance sheet without immediate dilution; the $600,000 reverse termination fee offers downside protection if the deal collapses.
- The headline “over $100 million” figure is aspirational (mostly success‑based milestones), but the partnership with a listed U.S. company opens a clear path toward U.S. commercialisation and provides third‑party validation.
- The news follows a string of positive operational updates (Executive Order response, supply agreements, JV progress), but this is the first large licensing deal for the core asset, making it genuinely new and market‑moving for a micro‑cap.
- Despite being a term sheet, the upfront cash, escrow commitment, and the public nature of the Jupiter press release give it more substance than a simple LOI; it is a material positive catalyst, not routine.
MDMA · Price
Company Overview
- PharmAla Biotech is a Canadian‑listed (CSE: MDMA) biotech company focused on the development, manufacturing, and sale of clinical‑grade MDMA and novel MDXX‑class molecules.
- Its commercial operations centre on LaNeo™ MDMA, which supplies clinical trials globally and is the backbone of the Cortexa joint venture in Australia – the only jurisdiction where MDMA therapy is legal for PTSD.
- The flagship pipeline asset is ALA‑002, a patented, non‑racemic MDMA formulation that is a FDA‑recognised Novel Chemical Entity. It was designed to reduce cardiovascular stress and abuse potential, addressing the main safety concerns of racemic MDMA.
- Additionally, the company has APA‑01, a novel MDXX molecule being spun into the Restora Neurosciences SPV for neurorehabilitation and TBI indications.
- PharmAla’s business model includes fee‑for‑service manufacturing, data‑for‑supply agreements, and IP licensing.
More from Pharmala Biotech Holdings Inc.
May 20, 2026 · 07:38